|
Toremifene in Treating Patients With Ovarian Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Toremifene in Treating Patients With Ovarian Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Toremifene in Treating Patients With Ovarian Cancer Clinical research trials and Toremifene in Treating Patients With Ovarian Cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Toremifene in Treating Patients With Ovarian Cancer. Toremifene in Treating Patients With Ovarian Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Toremifene in Treating Patients With Ovarian Cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Toremifene in Treating Patients With Ovarian Cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Toremifene in Treating Patients With Ovarian Cancer  Toremifene in Treating Patients With Ovarian Cancer
Toremifene in Treating Patients With Ovarian Cancer
For Condition: recurrent ovarian epithelial cancer,ovarian serous cystadenocarcinoma
Status: Completed
Sponsor(s): George Washington University ,
Synopsis: RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using toremifene may fight ovarian cancer by reducing the production of estrogen. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene in treating patients who have recurrent or refractory ovarian cancer.
Details: OBJECTIVES: - Determine the effects of toremifene in terms of response rate, duration of response, duration of survival, and toxicity in patients with chemotherapy resistant papillary carcinoma of the ovary. - Assess whether a dose response effect is likely for this regimen in these patients. - Assess quality of life of these patients. OUTLINE: This is a randomized study. Patients receive one of two doses of oral toremifene daily for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before therapy and then every 4 weeks during therapy. Patients are followed every 12 weeks until death. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed serous papillary carcinoma of the ovary - Recurrent or refractory disease following at least one regimen including paclitaxel, cisplatin, or carboplatin - Measurable disease outside of irradiated field - No CNS metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Zubrod 0-2 Life expectancy: - At least 16 weeks Hematopoietic: - Absolute neutrophil count at least 1,800/mm^3 - Platelet count at least 125,000/mm^3 - No history of thrombosis or thromboembolic events Hepatic: - Bilirubin no greater than 2.0 mg/dL Renal: - Creatinine no greater than 2.0 mg/dL Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 2 months after study - No other concurrent second malignancy or prior malignancy within past 5 years, except basal or squamous cell skin cancer or curatively treated stage I carcinoma of the cervix - No concurrent infection - At least 3 days since prior fever (unless due to tumor) - No other concurrent severe medical illness - No HIV positivity PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - No concurrent chemotherapy Endocrine therapy: - No prior tamoxifen or antiestrogen therapy Radiotherapy: - See Disease Characteristics - At least 6 months since prior radiotherapy - No concurrent radiotherapy except to symptomatic or potentially disabling bone lesion accompanied by other measurable disease Surgery: - Not specified Other: - No concurrent anticoagulants - No other concurrent therapeutic trials
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JamesAhlgren, Study Chair, George Washington University
George Washington University Cancer Center
Washington D.C., District of Columbia, 20037
United States
Additional Information:
Study ID Numbers: CDR0000067029; GWCC-7096,NCI-V99-1540
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003865
Other Ovarian Serous Cystadenocarcinoma Studies:
1. Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
2. Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
3. Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
4. Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
5. Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer
Related Studies:
Other ovarian serous cystadenocarcinoma Clinical Trials
Other District of Columbia Clinical Trials
Other Washington D.C. Clinical Trials
Toremifene in Treating Patients With Ovarian Cancer
|
|
|
|
|
|
|
|
